As of 2021, Canada has approved a total of 3 cellular therapeutic products for use on patients. These include the use of stem cells for the treatment of acute lymphoblastic leukemia (ALL), Adult B-cell Lymphoma, and Graft V Host disease. Most approved therapies use hematopoietic stem cells (HSC), found in bone marrow, blood, and the umbilical cord all contain HSCs. The future of stem cell treatments is dependent on Induced Pluripotent Stem Cell (IPSC) technology. IPSC technology involves reprogramming skin or blood cells into a pluripotent state .